

## Journal Information

|               |                                                   |
|---------------|---------------------------------------------------|
| Journal Title | CANCER BIOLOGY & MEDICINE                         |
| Publisher     | CHINA ANTI-CANCER ASSOC                           |
| ISSN          | 2095-3941                                         |
| E-ISSN        | 2095-3941                                         |
| Database      | Clarivate                                         |
| Domain        | Health Sciences, Life Sciences, Physical Sciences |

## Classification History

| Year      | A+ | A | B | C |
|-----------|----|---|---|---|
| 2026      |    | ✓ | ✓ |   |
| 2025      |    | ✓ | ✓ |   |
| 2024      |    | ✓ | ✓ |   |
| 2023      |    | ✓ | ✓ |   |
| 2021/2022 |    | ✓ | ✓ |   |
| 2020      |    | ✓ | ✓ |   |
| 2019      |    | ✓ | ✓ |   |
| 2018      |    | ✓ |   |   |

**Classification:** The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

## Recent Articles

|                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>RHBDF2 stabilizes SEC62 to sustain MDR1 biosynthesis and chemoresistance in breast cancer</b><br>2026-10-27 Pages 1-21<br>Authors: Yuanyuan Song, Lei Wang, Yumeng Liu et al.<br>DOI: 10.20892/j.issn.2095-3941.2026.0488                                                                                              |
| <b>Targeting KRAS condensates to counter therapeutic resistance in colorectal cancer</b><br>2026-10-27 Pages 1-6<br>Authors: Yi Zhang, Xingwen Wang, Jing Hu et al.<br>DOI: 10.20892/j.issn.2095-3941.2026.0573                                                                                                           |
| <b>Erratum to Flotillin1 promotes EMT of human small cell lung cancer via TGF-<math>\beta</math>2 signaling pathway</b><br>2026-10-14 Pages 1-5<br>Authors: Lianmei Zhao, Jie Li, Yueping Liu et al.<br>DOI: 10.20892/j.issn.2095-3941.2026.0738                                                                          |
| <b>A bispecific EGFR <math>\alpha</math>7; HER3 antibody<math>\alpha</math>13;drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303</b><br>2026-9-23 Pages 1-9<br>Authors: Huaqiang Zhou, Jiayi Shen, Jiaqing Liu et al.<br>DOI: 10.20892/j.issn.2095-3941.2026.0336 |

|                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non&amp;#x2013;small-cell lung cancer: a randomized, multicenter, phase II trial</b></p> <p>2026-9-17 Pages 1-14</p> <p>Authors: Mengjie Li, Caixia Liu, Fengming Ran et al.</p> <p>DOI: 10.20892/j.issn.2095-3941.2026.0311</p> |
| <p><b>Revisiting the immunosuppressive microenvironment in hepatocellular carcinoma: a functional taxonomy of immune cells and therapeutic targeting</b></p> <p>2026-9-15 Pages 1-26</p> <p>Authors: Jiaqian Zhang, Siwen Li, Xianglong Ma et al.</p> <p>DOI: 10.20892/j.issn.2095-3941.2026.0154</p>                              |
| <p><b>Erratum to From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management</b></p> <p>2026-9-8 Pages 1-1</p> <p>Authors: Junnan Xu, Kun Fang, Xiaoxi Li et al.</p> <p>DOI: 10.20892/j.issn.2095-3941.2026.0704</p>                                                   |
| <p><b>Migrasome-propagated ITG&amp;#x03B2;3-TGF&amp;#x03B2;1 circuit orchestrates breast cancer brain metastasis by reprogramming the microglial niche</b></p> <p>2026-9-8 Pages 1-32</p> <p>Authors: Song Wang, Xinmiao Xian, Guohao Gu et al.</p> <p>DOI: 10.20892/j.issn.2095-3941.2025.0803</p>                                |
| <p><b>cGAS&amp;#x2013;STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy</b></p> <p>2026-8-13 Pages 1-33</p> <p>Authors: Xinru Zhao, Shuai Meng, Hanzeng Cheng et al.</p> <p>DOI: 10.20892/j.issn.2095-3941.2026.0058</p>                                                               |
| <p><b>Rethinking nasopharyngeal carcinoma management: toward a low-toxicity, highly effective regimen with favorable tolerability and quality of life</b></p> <p>2026-8-8 Pages 1-8</p> <p>Authors: Yingni Zhang, Chunxian Ou, Cheng Xu</p> <p>DOI: 10.20892/j.issn.2095-3941.2026.0316</p>                                        |